Skip to main content
Springer logoLink to Springer
. 2022 Feb 28;40(3):679. doi: 10.1007/s10637-022-01226-6

Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors

Saiama N Waqar 1, Clifford Robinson 2, Anthony J Olszanski 2,3, Alexander Spira 4, Melissa Hackmaster 4, Luisa Lucas 5, Laura Sponton 6, Hulin Jin 6, Ursula Hering 6, Damien Cronier 6, Marianna Grinberg 6, Annick Seithel-Keuth 6, Ivan Diaz-Padilla 7, Jordan Berlin 8,
PMCID: PMC9098596  PMID: 35226229

Investigational New Drugs https://doi.org/10.1007/s10637-022–01216-8

The article Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors was originally published electronically on the publisher’s internet portal on 12 January 2022 without open access. The author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2022 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The original article has been corrected.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Articles from Investigational New Drugs are provided here courtesy of Springer

RESOURCES